Samsung Epis Holdings Co., Ltd. has been officially established as a new investment holding company, achieving a major milestone in the expansion of Samsung Bioepis. The company is set to be listed on the Korea Exchange (KRX) on November 24, 2025, after creating a new subsidiary on November 14, 2025. Samsung Bioepis will remain a wholly owned subsidiary of Samsung Epis Holdings, continuing to lead its biosimilar business.
Samsung Epis Holdings, as a dedicated biopharmaceutical holding company, will manage strategic investments in biotechnology with the goal of creating long-term value for both the company and its shareholders.
The company will target on advancing research and development (R&D) and exploring new growth opportunities, particularly through its subsidiaries. This structure will offer greater flexibility as well as independence in decision-making, strengthening Samsung Epis Holdings’ ability to pursue new opportunities in the biotech sector.
The new subsidiary of Samsung Epis Holdings will anchor on developing advanced biotechnology platforms. Its goal is to identify and create innovative therapies, advancing scalable technologies that can discover and develop new drug candidates. Collaboration with global pharmaceutical companies will play a major role in driving innovation in this area.
Founded in 2012, Samsung Bioepis will continue to focus on its core mission of developing and manufacturing as well as distributing high-quality biosimilars. The company’s portfolio now includes 11 biosimilas that are approved and sold globally.
In 2024, it achieved record sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. Looking forward, Samsung Bioepis plans to reinforce its R&D capabilities as well as extend its biosimilar portfolio to over 20 products. The company will also continue to grow its presence in immunology, oncology, ophthalmology, hematology, and nephrology, while exploring new therapeutic areas to address unmet patient needs.
Executive Statement
According to Kyung-Ah Kim, President and CEO of Samsung Epis Holdings, their new investment holding company is committed to uncovering investment opportunities in the biotechnology sector, driving the long-term growth of our subsidiaries. While continuing their commitment to biosimilars, they aim to expand into next-generation therapeutics and technologies.
